Keystone First Family of Health Plans

200 Stevens Drive Philadelphia, PA 19113



To: Keystone First, Keystone First Community HealthChoices (CHC) and Keystone First

VIP Choice Providers

Date: October 14, 2021

RE: Presumptive and Definitive Drug testing Payment Policy.

Summary: Effective November 15, 2021, when a definitive drug testing code and a presumptive drug testing code by instrumented chemistry analyzers (80307) are reported on the same date of service for the same member by the same independent clinical laboratory, Keystone First and Keystone First CHC will only reimburse for the presumptive test and will not allow separate reimbursement for the definitive drug testing code.

Keystone First, Keystone First CHC and Keystone First VIP Choice allow reimbursement of medically necessary presumptive and definitive drug testing when applicable codes are submitted.

When a definitive drug testing code for "any number of drug classes" (HCPCS Level II) is reported with a definitive drug testing code for a specific number of drug classes, only the "any number of drug classes" definitive drug testing code (G0659) will be eligible for reimbursement.

When a definitive drug testing code and a presumptive drug testing code by instrumented chemistry analyzers (80307) are reported on the same date of service for the same member by the same independent clinical laboratory, the Plan does not allow separate reimbursement for the definitive drug testing code.

The codes applicable to this policy are below.

Related Codes

80305	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only, includes sample validation when performed, per date of service	Reimbursable
80306	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation, includes sample validation when performed, per date of service	Reimbursable
80307	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay [e.g., EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	Reimbursable
80320- 80374, 83992	Drug test(s), individual types	Not reimbursable

80375-	Drug(s) or substance(s), definitive, qualitative or quantitative, not	Not
80377	otherwise specified	reimbursable
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	Reimbursable
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	Reimbursable
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	Reimbursable
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including,	Reimbursable

 ${\bf Coverage\ by\ Vista\ Health\ Plan,\ an\ independent\ licensee\ of\ the\ Blue\ Cross\ and\ Blue\ Shield\ Association.}$

	but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug	
	class(es), including metabolite(s) if performed	
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	Reimbursable

Questions:

If you have questions about this communication, please contact your Provider Account Executive or the Provider Services department at 1-800-521-6007.